Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A-M Boekstegers
MRD Response in a Refractory Paediatric T-All Patient Through Anti-Programmed Cell Death 1 (PD-1) Ab Treatment Associated With Induction of Fatal GvHD
Bone Marrow Transplantation
Transplantation
Hematology
Related publications
Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management
Therapeutic Advances in Medical Oncology
Oncology
Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-Cell-Mediated Injury in the Heart
Circulation
Cardiovascular Medicine
Physiology
Cardiology
PD-1 Receptor (PDCD1; PD-1; CD279); Programmed Cell Death 1 Ligand 1 (CD274 Molecule; PD-L1; B7-H1)
Science-Business eXchange
The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort
Oncotarget
Oncology
2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer
Open Forum Infectious Diseases
Oncology
Neurology
Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers
British Journal of Cancer
Cancer Research
Oncology
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
American Journal of Surgical Pathology
Anatomy
Forensic Medicine
Pathology
Surgery
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
JAMA Dermatology
Dermatology
Medicine
